Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients.

HIV medicine - 1 May 2010

Parczewski M, Leszczyszyn-Pynka M, Wnuk A, Urbañska A, Fuksiñska K, Bander D, Boroñ-Kaczmarska A

Abstract excerpt

OBJECTIVE: Prospective pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 allele can significantly reduce the number of cases of abacavir-related hypersensitivity among HIV-infected patients treated with this drug. The aim of this study was to establish the frequency of the HLA B*5701 variant in HIV-infected Poles. METHODS: The sequence-specific primer (SSP) test was used to assess the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dideoxynucleosides
Share to Drug Hypersensitivity

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Feasibility Studies

Share to HLA-B Antigens

Share to Poland

Share to Predictive Value of Tests

Share to Reverse Transcriptase Inhibitors

Share to Skin Tests

Source

Identifiers

PMID: 20070406
DOI: 10.1111/j.1468-1293.2009.00787.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients.PMID 20070406Read ↗

HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B*57:01 genotyping to predict abacavir hypersensitivity reaction in Spain.Semantic proximity Read ↗

Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701.Semantic proximity Read ↗

Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01.Semantic proximity Read ↗

Novel Sensitive, Specific and Rapid Pharmacogenomic test for the Prediction of Abacavir Hypersensitivity Reaction: HLA-B*57:01 Detection by Real-Time PCRSemantic proximity Read ↗

High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia.Semantic proximity Read ↗

HLA-B*5701 frequency in Chilean HIV-infected patients and in general population.Semantic proximity Read ↗

Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir.Semantic proximity Read ↗

Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.Semantic proximity Read ↗

HLA-B*5701 screening for hypersensitivity to abacavir.Semantic proximity Read ↗

HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.Semantic proximity Read ↗

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjectsSemantic proximity Read ↗

HLA-B*57:01 typing in a Malaysian cohort: implications of abacavir hypersensitivity in people living with HIV.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.